AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1617762 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 113
Study 6439700 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast neutron radiation therapy
Number of subjects: 40
Study 6439700 — intervention group
Group type: COMPARATOR
Intervention: Conventional photon radiation therapy
Number of subjects: 40
Study 31678306 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin
Number of subjects: 1968
Study 31678306 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 1968
Study 31678306 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistin
Number of subjects: 1968
Study 31349791 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 32
Study 31349791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative High-Intensity Interval Training (C-HIIT)
Number of subjects: 32
Study 31349791 — intervention group
Group type: COMPARATOR
Intervention: Sedentary condition
Number of subjects: 32
Study 29117929 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully automated Web-based program (ANODE)
Number of subjects: 120
Study 29117929 — intervention group
Group type: COMPARATOR
Intervention: General nutritional advice (Control)
Number of subjects: 120
Study 26159382 — intervention group
Group type: EXPERIMENTAL
Intervention: etch‐and‐rinse+moist dentin (ERm)
Number of subjects: 39
Study 26159382 — intervention group
Group type: EXPERIMENTAL
Intervention: etch‐and‐rinse+dry dentin (ERd)
Number of subjects: 39
Study 26159382 — intervention group
Group type: EXPERIMENTAL
Intervention: selective enamel etching (Set)
Number of subjects: 39
Study 26159382 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐etch (SE)
Number of subjects: 39
Study 24053756 — intervention group
Group type: EXPERIMENTAL
Intervention: Human advisor
Number of subjects: 218
Study 24053756 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated interactive voice response advisor
Number of subjects: 218
Study 22153015 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (6% HES 130/0.4) + high volume hemofiltration (HVHF) for 72 hours
Number of subjects: 108
Study 22153015 — intervention group
Group type: COMPARATOR
Intervention: Control group (6% hydroxyethyl starch (6% HES 130/0.4) for volume resuscitation)
Number of subjects: 108
Study 19564761 — intervention group
Group type: EXPERIMENTAL
Intervention: Godelive Denys-Struyf (GDS) method
Number of subjects: 137
Study 19564761 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 137
Study 16859871 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self‐management Program (CDSMP)
Number of subjects: 320
Study 16859871 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 320
Study 15451131 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation to quit smoking
Number of subjects: 72
Study 10706013 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of oestrogen
Number of subjects: 25
Study 10706013 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of oestrogen and progesterone
Number of subjects: 25
Study 9376207 — intervention group
Group type: EXPERIMENTAL
Intervention: Video supplement to informed consent
Number of subjects: 186
Study 9376207 — intervention group
Group type: COMPARATOR
Intervention: Pamphlet review before discussion
Number of subjects: 186
Study 1403040 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA and etoposide
Number of subjects: 72
Study 3904391 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 5507
Study 3904391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5507
Study 3109340 — intervention group
Group type: EXPERIMENTAL
Intervention: dihydroergocristine
Number of subjects: 97
Study 3109340 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 97
Study 31162838 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel + carboplatin (nab-pac/carbo)
Number of subjects: 336
Study 31162838 — intervention group
Group type: COMPARATOR
Intervention: nab-paclitaxel + gemcitabine (nab-pac/gem)
Number of subjects: 336
Study 28833748 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation, cognitive behavioural therapy, and life review methods
Number of subjects: 6
Study 27015660 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral epigallocatechin-3-gallate (EGCG) treatment for 4 months
Number of subjects: 17
Study 27015660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 25773130 — intervention group
Group type: EXPERIMENTAL
Intervention: PCHMS (web-based personally controlled health management system)
Number of subjects: 747
Study 25773130 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PCHMS access)
Number of subjects: 747
Study 25773130 — intervention group
Group type: EXPERIMENTAL
Intervention: PCHMS (web-based personally controlled health management system) among sexually active participants
Number of subjects: 747
Study 25773130 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PCHMS access) among sexually active participants
Number of subjects: 747
Study 23110746 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 84
Study 23110746 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 84
Study 21134123 — intervention group
Group type: EXPERIMENTAL
Intervention: IV acetaminophen 1,000mg q6h
Number of subjects: 213
Study 21134123 — intervention group
Group type: EXPERIMENTAL
Intervention: IV acetaminophen 650mg q4h
Number of subjects: 213
Study 21134123 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care treatment
Number of subjects: 213
Study 18249211 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/d
Number of subjects: 38
Study 18249211 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg/d
Number of subjects: 38
Study 16780480 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 10% potassium hydroxide solution
Number of subjects: 20
Study 16780480 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 20
Study 14533336 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic Oral-B
Number of subjects: 46
Study 14533336 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-B Advantage 30
Number of subjects: 46
Study 14533336 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Precision
Number of subjects: 46
Study 14533336 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquafresh
Number of subjects: 46
Study 10974801 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathy-induction condition
Number of subjects: 205
Study 10974801 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 205
Study 10974801 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathy condition (women)
Number of subjects: 205
Study 10974801 — intervention group
Group type: EXPERIMENTAL
Intervention: Child defendant gender (girl)
Number of subjects: 205
Study 8649700 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly stripping of membranes
Number of subjects: 142
Study 8649700 — intervention group
Group type: COMPARATOR
Intervention: Weekly gentle cervical examinations
Number of subjects: 142
Study 1371197 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor-specific transfusions (DST) and continuous intravenous cyclosporine (CsA) initiated 24 hr before transplantation
Number of subjects: 22
Study 1371197 — intervention group
Group type: COMPARATOR
Intervention: Sequential therapy with Minnesota antilymphoblast globulin, azathioprine, and steroids with subsequent conversion to CsA (Control)
Number of subjects: 22
Study 6378423 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 41
Study 30773542 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 °C RF‐APGD plasma jet treatment for 20 s
Number of subjects: 52
Study 30773542 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 °C RF‐APGD plasma jet treatment for 20 s
Number of subjects: 52
Study 30773542 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 52
Study 30773542 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 °C RF‐APGD plasma jet treatment for 20 s
Number of subjects: 52
Study 30773542 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 °C RF‐APGD plasma jet treatment for 20 s
Number of subjects: 52
Study 29791672 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care teaching program after radical prostatectomy (oral guidance, writing, and telephonic reinforcement)
Number of subjects: 68
Study 29791672 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 68
Study 25730292 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical liposomal lidocaine
Number of subjects: 281
Study 25730292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study 24798104 — intervention group
Group type: EXPERIMENTAL
Intervention: Early sympathectomy (Group I) before Step 2 of the WHO analgesic ladder
Number of subjects: 109
Study 24798104 — intervention group
Group type: COMPARATOR
Intervention: Standard analgesics according to the WHO ladder followed by sympathectomy as the fourth step (Group II)
Number of subjects: 109
Study 21949243 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic walking (NW) exercise program, 60-min supervised sessions twice a week for 9 weeks
Number of subjects: 0
Study 21949243 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 0
Study 20597708 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-cholinergic load
Number of subjects: 112
Study 18596959 — intervention group
Group type: EXPERIMENTAL
Intervention: Broccoli-rich diet
Number of subjects: 0
Study 18596959 — intervention group
Group type: COMPARATOR
Intervention: Pea-rich diet
Number of subjects: 0
Study 15762938 — intervention group
Group type: EXPERIMENTAL
Intervention: Own perspective
Number of subjects: 0
Study 15762938 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined in-group members' perspective
Number of subjects: 0
Study 15762938 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined out-group members' perspective
Number of subjects: 0
Study 11560538 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/d of sibutramine continuously throughout weeks 1-48 (n = 405)
Number of subjects: 1102
Study 11560538 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/d of sibutramine intermittently during weeks 1-12, 19-30, and 37-48 (n = 395)
Number of subjects: 1102
Study 11560538 — intervention group
Group type: COMPARATOR
Intervention: Placebo for weeks 5-48 (n = 201)
Number of subjects: 1102
Study 9692129 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleurodesis using a small percutaneous catheter (Cystofix catheter, CH10, 65 cm)
Number of subjects: 18
Study 9692129 — intervention group
Group type: COMPARATOR
Intervention: Conventional large bore chest tube (CH24)
Number of subjects: 18
Study 7799583 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative therapy
Number of subjects: 65
Study 3391878 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin acistrate (EA) 500 mg tid for three days
Number of subjects: 61
Study 3391878 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin base (EB) enterotablets 500 mg tid for three days
Number of subjects: 61
Study 3391878 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin base (EB) enterocapsules 500 mg tid for three days
Number of subjects: 61
Study 3391878 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin stearate (ES) 500 mg tid for three days
Number of subjects: 61
Study 31181242 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect resin composite veneers (Estenia)
Number of subjects: 48
Study 31181242 — intervention group
Group type: COMPARATOR
Intervention: Ceramic laminate veneers (IPS Empress Esthetic)
Number of subjects: 48
Study 28726440 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength at Home Men's Program (SAH‐M)
Number of subjects: 125
Study 28726440 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU)
Number of subjects: 125
Study 24763187 — intervention group
Group type: EXPERIMENTAL
Intervention: Veterans Physical Activity Questionnaire (VAPAQ)
Number of subjects: 55
Study 23417658 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular phase
Number of subjects: 67
Study 23417658 — intervention group
Group type: EXPERIMENTAL
Intervention: Periovulatory phase
Number of subjects: 67
Study 23417658 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase
Number of subjects: 67
Study 23417658 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-menses to ovulation
Number of subjects: 67
Study 23417658 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase among women with CD4 counts of <350 cells/µL
Number of subjects: 67
Study 23417658 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall shedding frequency and magnitude
Number of subjects: 67
Study 20878269 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen and fenretinide
Number of subjects: 426
Study 20878269 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 426
Study 19406273 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 2322
Study 19406273 — intervention group
Group type: COMPARATOR
Intervention: Objective markers of HF severity (ejection fraction, B-type natriuretic peptide, peak oxygen consumption)
Number of subjects: 2322
Study 19406273 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis including age, gender, cardiopulmonary exercise testing duration, NYHA class, 6-minute walk distance, and peak respiratory exchange ratio
Number of subjects: 2322
Study 17343007 — intervention group
Group type: EXPERIMENTAL
Intervention: Panax notoginseng saponins (PNS)
Number of subjects: 50
Study 17343007 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional treatment only)
Number of subjects: 50
Study 15531495 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200,000 IU)
Number of subjects: 138
Study 15531495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 11816898 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 0
Study 11816898 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 10193295 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil with propofol
Number of subjects: 12
Study 10193295 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil with isoflurane
Number of subjects: 12
Study 10193295 — intervention group
Group type: COMPARATOR
Intervention: remifentanil (combined with either propofol or isoflurane)
Number of subjects: 12
Study 7818448 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warming
Number of subjects: 8
Study 7818448 — intervention group
Group type: COMPARATOR
Intervention: Shivering
Number of subjects: 8
Study 3382461 — intervention group
Group type: COMPARATOR
Intervention: 2 mg cianopramine (acute administration)
Number of subjects: 14
Study 3382461 — intervention group
Group type: COMPARATOR
Intervention: 1, 2, and 3 mg cianopramine (chronic administration)
Number of subjects: 14
Study 3382461 — intervention group
Group type: COMPARATOR
Intervention: 3 mg cianopramine (superimposed single dose after chronic administration)
Number of subjects: 14
Study 28643066 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical exosuit
Number of subjects: 20
Study 28643066 — intervention group
Group type: COMPARATOR
Intervention: Control (no exosuit)
Number of subjects: 20
Study 27619026 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar electrocautery (BC)
Number of subjects: 70
Study 27619026 — intervention group
Group type: COMPARATOR
Intervention: Cold dissection (CD)
Number of subjects: 70
Study 27619026 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 25341739 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation (RFA)
Number of subjects: 0
Study 25341739 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation (RFA) in patients <50 years old
Number of subjects: 0
Study 25341739 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation (RFA) in patients >50 years old
Number of subjects: 0
Study 25341739 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drugs (AADs)
Number of subjects: 0
Study 23548855 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (440 mg of Mg oxide 3 times per week for 6 months)
Number of subjects: 54
Study 23548855 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same administration protocol as Mg group)
Number of subjects: 54
Study 23548855 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 54
Study 21518840 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg efavirenz with 600 mg rifampin/day
Number of subjects: 11
Study 21518840 — intervention group
Group type: COMPARATOR
Intervention: 600 mg efavirenz/day
Number of subjects: 11
Study 19522323 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictures of faces
Number of subjects: 0
Study 19522323 — intervention group
Group type: COMPARATOR
Intervention: Pictures of faces (own, friend's, unknown)
Number of subjects: 0
Study 16723928 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led case management (Evercare)
Number of subjects: 132
Study 16723928 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 132
Study 15610326 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted, patient-centered intervention
Number of subjects: 886
Study 15610326 — intervention group
Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 886
Study 11356387 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-irradiation (192Ir)
Number of subjects: 29
Study 8568310 — intervention group
Group type: EXPERIMENTAL
Intervention: US inactivated split-virus vaccine
Number of subjects: 555
Study 8568310 — intervention group
Group type: EXPERIMENTAL
Intervention: Russian live attenuated, cold-adapted vaccine
Number of subjects: 555
Study 1369722 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (600 mg for 60 days)
Number of subjects: 82
Study 1369722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 91023 — intervention group
Group type: EXPERIMENTAL
Intervention: A combination of 50 mg acarbose and 14.5 g guar gum
Number of subjects: 8
Study 91023 — intervention group
Group type: COMPARATOR
Intervention: Acarbose alone
Number of subjects: 8
Study 30010808 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention for 24 weeks
Number of subjects: 40
Study 30010808 — intervention group
Group type: COMPARATOR
Intervention: Health education control intervention
Number of subjects: 40
Study 30010808 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention for participants attending ≥25% of scheduled visits
Number of subjects: 40
Study 28657948 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Readmission Reduction Program (2010-2014)
Number of subjects: 5122240
Study 28657948 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Readmission Reduction Program (2010-2012)
Number of subjects: 5122240
Study 25748698 — intervention group
Group type: EXPERIMENTAL
Intervention: hANP + DA (1-3 μg·kg·min)
Number of subjects: 24
Study 25748698 — intervention group
Group type: COMPARATOR
Intervention: hANP + furosemide (10-30 mg injection)
Number of subjects: 24
Study 25748698 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 24812742 — intervention group
Group type: EXPERIMENTAL
Intervention: Edgewise brackets without deep bite
Number of subjects: 40
Study 24812742 — intervention group
Group type: COMPARATOR
Intervention: Alexander brackets
Number of subjects: 40
Study 24812742 — intervention group
Group type: EXPERIMENTAL
Intervention: Edgewise brackets with deep bite
Number of subjects: 40
Study 24812742 — intervention group
Group type: COMPARATOR
Intervention: Alexander brackets with deep bite
Number of subjects: 40
Study 22737876 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound betamethasone injection 1 ml and benzathine penicillin 1 200 000 U, deeply injected into muscles on hips, one time.
Number of subjects: 60
Study 22737876 — intervention group
Group type: COMPARATOR
Intervention: Desloratadine 5 mg orally once a day and amoxicillin capsules 0.5 mg orally three times a day, taken for one week.
Number of subjects: 60
Study 20334446 — intervention group
Group type: EXPERIMENTAL
Intervention: Polycap (polypill; aspirin, ramipril, simvastatin, atenolol, hydrochlorothiazide)
Number of subjects: 195
Study 20334446 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 195
Study 20334446 — intervention group
Group type: EXPERIMENTAL
Intervention: Polycap
Number of subjects: 195
Study 17610528 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC114/r (300/100 mg bid) for 7 days
Number of subjects: 12
Study 17610528 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC114/r (300/100 mg bid) plus TDF (300 mg qd)
Number of subjects: 12
Study 17610528 — intervention group
Group type: COMPARATOR
Intervention: TMC114/r (300/100 mg bid)
Number of subjects: 12
Study 16139140 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 21
Study 16139140 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 21
Study 16139140 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 21
Study 16139140 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal vasoconstrictor responses)
Number of subjects: 21
Study 11937314 — intervention group
Group type: EXPERIMENTAL
Intervention: PVACE‐BOPx3 + autotransplant (Arm A)
Number of subjects: 126
Study 11937314 — intervention group
Group type: EXPERIMENTAL
Intervention: PVACE‐BOPx5 (Arm B)
Number of subjects: 126
Study 11937314 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy with CLVPP or ABVD (not part of the trial)
Number of subjects: 126
Study 11937314 — intervention group
Group type: EXPERIMENTAL
Intervention: PVACE‐BOP therapy in the poorest risk group
Number of subjects: 126
Study 11937314 — intervention group
Group type: COMPARATOR
Intervention: Autotransplant in first CR
Number of subjects: 126